Bayer: Embolism trials

The registry lists 11 Embolism studies with Bayer as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Switching Study From Warfarin to RivaroxabanCompletedNCT01507051Phase 1Results posted
• Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 InducerCompletedNCT00786422Phase 2Results posted
• Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial FibrillationCompletedNCT03746301
• Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic AcidCompletedNCT03746275
• Bioequivalence Study of RivaroxabanCompletedNCT02537457Phase 1
• Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsCompletedNCT02537405Phase 1
• Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation PatientsCompletedNCT01925755
• Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA RegionCompletedNCT01800006
• Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in AsiaCompletedNCT01750788
• Xarelto for Prevention of Stroke in Patients With Atrial FibrillationCompletedNCT01606995
• Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)CompletedNCT00839163Phase 2